95 related articles for article (PubMed ID: 7816386)
21. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients.
Malviya G; Anzola KL; Podestà E; Laganà B; Del Mastro C; Dierckx RA; Scopinaro F; Signore A
Mol Imaging Biol; 2012 Oct; 14(5):637-46. PubMed ID: 22127469
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of glutamate-sensitive radiopharmaceuticals: Technetium-99m-glutamic acid and technetium-99m-diethylenetriaminepentaacetic acid-bis(glutamate) conjugate for tumor imaging.
Kakkar D; Tiwari AK; Chuttani K; Kaul A; Singh H; Mishra AK
Cancer Biother Radiopharm; 2010 Dec; 25(6):645-55. PubMed ID: 21204758
[TBL] [Abstract][Full Text] [Related]
23. A 99Tcm-labelled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits.
Brouwers AH; Laverman P; Boerman OC; Oyen WJ; Barrett JA; Harris TD; Edwards DS; Corstens FH
Nucl Med Commun; 2000 Nov; 21(11):1043-50. PubMed ID: 11192710
[TBL] [Abstract][Full Text] [Related]
24.
Rashed HM; Marzook FA; Farag H
Radiol Med; 2016 Dec; 121(12):935-943. PubMed ID: 27586132
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of a bis-(N-sec-butyl-dithiocarbamato)-nitrido-99mTc complex: a potential new radiopharmaceutical for brain perfusion studies.
Zhang J; Wang X; Liu J
Appl Radiat Isot; 2005 Jan; 62(1):33-7. PubMed ID: 15498682
[TBL] [Abstract][Full Text] [Related]
26. Cysteine, a chelating moiety for synthesis of 99Tcm radiopharmaceuticals. III: Functionalization of hydroxy group for 99Tcm chelation.
Chatterjee M; Banerjee S
Nucl Med Commun; 1990 Apr; 11(4):305-12. PubMed ID: 2362743
[TBL] [Abstract][Full Text] [Related]
27. 99Tcm-exametazime-labelled leucocytes: effect of volume and concentration of exametazime on labelling efficiency, and clinical protocol for high efficiency multi-dose radiolabelling.
Sampson CB; Solanki C; Barber RW
Nucl Med Commun; 1991 Aug; 12(8):719-23. PubMed ID: 1780111
[TBL] [Abstract][Full Text] [Related]
28. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
29. A synthetic macromolecule for sentinel node detection: (99m)Tc-DTPA-mannosyl-dextran.
Vera DR; Wallace AM; Hoh CK; Mattrey RF
J Nucl Med; 2001 Jun; 42(6):951-9. PubMed ID: 11390562
[TBL] [Abstract][Full Text] [Related]
30. Technetium-99m labeling of N-[N-(3-diphenylphosphino propionyl)glycyl]cysteine (PN2S-OH) and its methyl ester derivative (PN2S-OMe).
Visentin R; Giron MC; Bello M; Mazzi U
Nucl Med Biol; 2004 Jul; 31(5):655-62. PubMed ID: 15219285
[TBL] [Abstract][Full Text] [Related]
31. Preparation and pharmacological evaluation of a new radiopharmaceutical, technetium-99m-5-fluorouracil, for tumor scintigraphy.
Kumar S; Kumar Mishra A; Chhikara BS; Chuttani K; Kumar Sharma R
Hell J Nucl Med; 2008; 11(2):91-5. PubMed ID: 18815662
[TBL] [Abstract][Full Text] [Related]
32. A comparative study of 99Tcm-HMPAO and 99Tcm-ECD as a leukocyte labelling agent.
Kao CH; Huang WT; Wang YL; Lin KS; Lo JM; Wang SJ
Nucl Med Commun; 1994 Apr; 15(4):294-7. PubMed ID: 8072744
[TBL] [Abstract][Full Text] [Related]
33. Technetium-99m labelling of the anti-tumour antibody PR1A3 by photoactivation.
Stalteri MA; Mather SJ
Eur J Nucl Med; 1996 Feb; 23(2):178-87. PubMed ID: 8925853
[TBL] [Abstract][Full Text] [Related]
34. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
Zhang X; Chen X
Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
[TBL] [Abstract][Full Text] [Related]
35. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
36. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
37. Technetium-labelled autologous lymphocytes: clinical protocol for radiolabelling using a high concentration and low volume of 99Tcm-exametazime.
Sampson CB; Goffin E
Nucl Med Commun; 1991 Oct; 12(10):875-8. PubMed ID: 1792022
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of reduction-mediated labelling of antibodies with technetium-99m.
Zhang ZM; Ballinger JR; Sheldon K; Boxen I
Int J Rad Appl Instrum B; 1992 Aug; 19(6):607-9. PubMed ID: 1522015
[TBL] [Abstract][Full Text] [Related]
39. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
40. 2-aminoethylphosphonic acid: biodistribution of a naturally occurring phosphonate after labelling with technetium-99m.
Castronovo FP; Kopiwoda S; Peterson M
Nucl Med Commun; 1996 Oct; 17(10):902-6. PubMed ID: 8951913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
